Press Releases

May 17, 2018

 First patient enrolled in Phase 3 trial of IBAT inhibitor A4250 in PFIC   Elobixibat in Japan becomes first IBAT inhibitor approved in the world   Management to host conference call and webcast today at 8:30 a.m. EDT  BOSTON , May 17, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.

May 16, 2018

— Pivotal program in rare and life-threatening pediatric liver disorder underway — — Data intended to provide support for anticipated drug approval applications in US and EU — BOSTON , May 16, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver

April 30, 2018

BOSTON , April 30, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the Deutsche Bank 43 rd